Company: PSTV
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047698
Chunk: 184

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 184
---
0.7 million, which is expected to be recognized as a result of vesting under service conditions over a weighted average period of 2.8 years.

17.     Segment Information  The Company operates under one reportable business segment to advance the development, manufacturing and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases. The determination of a single reportable business segment is consistent with the consolidated financial information regularly provided to the Company’s CODM. All of the Company's long-term assets and operations are located in the United States. The Company’s CODM is its Chief Executive Officer, who reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance, including comparing actual results to budgets and forecasts to assess variances, identify trends, and guide strategic planning.  In addition to the significant expense categories included within the consolidated statements of operations, the below disaggregated amounts comprise significant research and development and general and administrative expenses. These expenses consist of (1) clinical, manufacturing and research contracts for research and development programs, (2) personnel-related expenses, including salaries, benefits and share-based compensation, (3) professional fees, including third-party costs for goods and services such as lab supplies and contract research, and legal and other professional expenses, and (4) facility and other overhead expenses, including depreciation, occupancy, travel, insurance and other costs.  

98

        (in thousands)
        Twelve Months Ended December 31,2024
         
        Twelve Months Ended December 31,2023

        Research and development

          Clinical, development and licensing expenses
        $
        4,549
         
        $
        5,062

          Personnel related expenses
         
        3,026

        2,852

          Professional fees
         
        1,733

        635

          Facility and other overhead expenses
         
        1,272

        1,141

             Total research and development
         
        10,580

        9,690

        General and administrative

          Personnel related expenses
         
        3,454

        3,006

          Professional expenses
         
        4,828

        3,870

          Facility and other overhead expenses
         
        1,657

        1,668